000162920 001__ 162920
000162920 005__ 20251017144622.0
000162920 0247_ $$2doi$$a10.1016/j.inpsyc.2025.100129
000162920 0248_ $$2sideral$$a145439
000162920 037__ $$aART-2025-145439
000162920 041__ $$aeng
000162920 100__ $$aMolina-Torres, Nora$$uUniversidad de Zaragoza
000162920 245__ $$aClinical parameters predicted the progression to dementia in oldest old patients with mild cognitive impairment (MCI)
000162920 260__ $$c2025
000162920 5060_ $$aAccess copy available to the general public$$fUnrestricted
000162920 5203_ $$aBackground: This study intends to assess to what extent instruments commonly used in clinical practice, as well as plasma p-tau-181, can predict the progression from MCI to dementia. The usefulness of a disease progression model (DPM) is also explored.
Methods: A longitudinal, prospective nested case-control study was conducted with patients from the Geriatrics outpatient clinics who met the MCI International Working Group criteria. The patients had a first clinical interview and two follow-ups after 12 and 24 months. Validated Spanish instruments were used for assessment, including the Mini-Mental State Examination (MMSE), the clock test, verbal fluency, the EURO-D depression scale, Barthel’s Index, and Lawton’s Index. P-tau-181 analysis was performed with SIMOA (Single MOlecule Array). A robust parametric disease progression model (RPDPM) was developed.
Results. Fifty-nine patients fulfilled the inclusion criteria. The median age was 82.7 + /−8.7 years, 93 % had amnestic MCI and 45.8 % progressed to dementia (ICD-11 criteria) in two years. P-tau-181 was not prognostic. An RPDPM with the MMSE, clock test, and Lawton’s Index could predict progression to dementia with an AUC of 0.945.
Conclusion: A combination of the MMSE, clock test, and Lawton’s Index in a DPM model predicted progression from MCI to dementia best. P-tau and other blood biomarkers did not predict progression. Our results highlight the strength of clinical variables to predict the progression of MCI.
000162920 536__ $$9info:eu-repo/grantAgreement/ES/DGA/A19-23R$$9info:eu-repo/grantAgreement/ES/FIS/PI21-00286$$9info:eu-repo/grantAgreement/ES/ISCIII/FEDER/PI21-00372
000162920 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000162920 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000162920 700__ $$aPlatero, Carlos
000162920 700__ $$aPérez-Berasategui, Oscar$$uUniversidad de Zaragoza
000162920 700__ $$aAndrés-Benito, Pol
000162920 700__ $$aPovedano, Mónica
000162920 700__ $$aMesa-Lampré, Pilar
000162920 700__ $$aAbadía-Morales, María
000162920 700__ $$0(orcid)0000-0001-5193-7782$$aCalvo, Ana-Cristina$$uUniversidad de Zaragoza
000162920 700__ $$0(orcid)0000-0002-9098-655X$$aLobo, Antonio$$uUniversidad de Zaragoza
000162920 700__ $$0(orcid)0000-0003-2284-7862$$aDe La Cámara-Izquierdo, Concepción$$uUniversidad de Zaragoza
000162920 700__ $$0(orcid)0000-0001-5687-6704$$aOsta, Rosario$$uUniversidad de Zaragoza
000162920 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000162920 7102_ $$11001$$2420$$aUniversidad de Zaragoza$$bDpto. Anatom.,Embri.Genét.Ani.$$cÁrea Genética
000162920 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000162920 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000162920 773__ $$g(2025), 100129 [8 pp.]$$pInt. psychogeriatr.$$tInternational Psychogeriatrics$$x1041-6102
000162920 8564_ $$s2754218$$uhttps://zaguan.unizar.es/record/162920/files/texto_completo.pdf$$yVersión publicada
000162920 8564_ $$s2494648$$uhttps://zaguan.unizar.es/record/162920/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000162920 909CO $$ooai:zaguan.unizar.es:162920$$particulos$$pdriver
000162920 951__ $$a2025-10-17-14:22:28
000162920 980__ $$aARTICLE